Company BiVictriX Therapeutics Plc

Equities

BVX

GB00BNXH3K91

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed London S.E. Other stock markets 07:34:52 2024-05-09 am EDT			5-day change	1st Jan Change
11 ^GBX	-4.35%		-4.35%	+4.76%

Apr. 17	Bivictrix granted FDA orphan drug status for rare cancer treatment	AN
Apr. 17	BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	MT

BiVictriX Therapeutics plc is a drug discovery and development company. The Company is focused on leveraging clinical experience to develop highly selective cancer therapeutics. The Company generates a proprietary pipeline of Bi-Cygni Antibody Drug Conjugate (ADC) therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints, on tumour cells, which are largely absent from healthy cells. The Company utilizes these novel Bi-Cygni fingerprints, together with the Companyâs novel Antibody Drug Conjugate therapeutic design, to develop therapeutics to target cancers. Its pipeline includes BVX001, BVX002 and BVX003. Its lead program: BVX001 is a Bi-Cygni ADC designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with Acute Myeloid Leukaemia (AML), and in subpopulations of cancer cells from patients with other haematological cancers.

Number of employees: 17

Managers	Title	Age	Since
Tiffany Thorn FOU	Founder	37	15-12-31
Adrian Howd DFI	Director of Finance/CFO	52	23-10-02
Simon Wallwork SEC	Corporate Secretary	-	21-06-21
Oliver Schon PRN	Corporate Officer/Principal	-	21-09-13

Members of the board	Title	Age	Since
Michael Kauffman CHM	Chairman	60	22-01-15
William Paris BRD	Director/Board Member	73	21-09-21
Susan Lowther BRD	Director/Board Member	65	21-09-21
Tiffany Thorn FOU	Founder	37	15-12-31
Robert Hawkins BRD	Director/Board Member	69	21-09-21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	82,526,088	52,278,670 ( 63.35 %)	0	63.35 %

Name	Equities	%	Valuation
DBW FM Ltd. 14.38 %	11,870,021	14.38 %	2 M p
Robert Keith 11.70 %	9,652,434	11.70 %	1 M p
Canaccord Genuity Wealth Ltd. 10.21 %	8,428,423	10.21 %	1 M p
SpreadEx Ltd. 4.110 %	3,391,866	4.110 %	482 052 p
Tiffany Thorn 1.978 %	1,632,500	1.978 %	232 011 p
Iain Ross 0.6119 %	505,000	0.6119 %	71 771 p
Robert Hawkins 0.2726 %	225,000	0.2726 %	31 977 p
Michael Kauffman 0.0909 %	75,000	0.0909 %	10 659 p
William Paris 0.0909 %	75,000	0.0909 %	10 659 p
Susan Lowther 0.0881 %	72,727	0.0881 %	10 336 p

BiVictriX Therapeutics Plc

Mereside Alderley Park Alderley Edge

SK10 4TG, Macclesfield

http://www.bivictrix.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.115 GBP

Average target price

0.66 GBP

Spread / Average Target

+473.91%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIVICTRIX THERAPEUTICS PLC	+4.76%	11.86M
MODERNA, INC.	+22.56%	46.71B
IQVIA HOLDINGS INC.	-1.51%	41.52B
LONZA GROUP AG	+48.83%	41.8B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.13%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.26B
MEDPACE HOLDINGS, INC.	+26.45%	11.98B
BIO-TECHNE CORPORATION	-0.14%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.08B

Other Biotechnology & Medical Research